| ncRNA | non-coding RNA |
| vtRNA | vault RNA |
| 3′-UTR | three prime untranslated region |
| PrCa | Prostate Cancer |
| PSA | Prostate-Specific Antigen |
| nc886 | non-coding RNA 886 (vtRNA2-1) |
| Pre-miR-886 | hsa-mir-886 precursor of microRNAs hsa-miR-886-3p and 5p |
| snc886s | small non-coding RNA derived from nc886 |
| snc886-3p | small non-coding RNA derived from nc886 at 3′ region |
| snc886-5p | small non-coding RNA derived from nc886 at 5′ region |
| svtRNA2-1 | small non-coding RNA derived from vtRNA2-1/nc886 |
| PAR-CLIP | photoactivatable ribonucleoside-enhanced crosslinking and immunoprecipitation |
| PRAD-TCGA | Prostate Adenocarcinoma—The Cancer Genome Atlas |
| SRA | Sequence Read Archive |
| GEO | Gene Expression Omnibus |
| DEG | Differentially Expressed Gene |
| MFE | Maximum Free Energy |
| RISC | RNA-induced silencing complex |
| qRT-PCR | quantitative Reverse Transcription Polymerase Chain Reaction |
| TSS200nt | 200nt region upstream to the transcription start site |
| GSEA | Gene Set Enrichment Analysis |
| MTT | 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide |